Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032309 | 0.91 | TNNI3K (0.45) | TNNI3KEGFRSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL20372757 | 0.83 | CCR5 (0.41) | SMN1; SMN2CCR5NR1I2CA2CA1 | |
| SCHEMBL21164434 | 0.83 | PSIP1 (0.44) | SMN1; SMN2CCR5NR1I2CA2CA1 | |
| SCHEMBL18713706 | 0.83 | HDAC4 (0.50) | TNNI3KEGFRSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL21164504 | 0.82 | CA2 (0.50) | CCR5CA2CA1 | |
| SCHEMBL21164503 | 0.81 | CCR5 (0.39) | SMN1; SMN2KMT2ACCR5NR1I2CA2 | |
| SCHEMBL17367964 | 0.76 | DRD2 (0.42) | SMN1; SMN2CCR5CA2CA1 | |
| SCHEMBL12278151 | 0.76 | TNNI3K (0.62) | TNNI3KEGFRSMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL27979185 | 0.75 | CA2 (0.52) | CA2CA1 | |
| SCHEMBL22084580 | 0.73 | TNNI3K (0.49) | TNNI3KEGFRSMN1; SMN2L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | TNNI3K 933/4885EGFR 3433/4885SMN1; SMN2 3998/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TNNI3K 933/4885EGFR 3433/4885SMN1; SMN2 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.